Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Cross Below Fifty Day Moving Average of $1.06

Adaptimmune Therapeutics plc (NASDAQ:ADAP) crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $1.06 and traded as low as $0.86. Adaptimmune Therapeutics shares last traded at $0.87, with a volume of 774,375 shares changing hands.

Wall Street Analyst Weigh In

ADAP has been the subject of several recent analyst reports. StockNews.com raised shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, June 3rd. Scotiabank began coverage on shares of Adaptimmune Therapeutics in a research report on Thursday, May 30th. They issued a “sector outperform” rating and a $3.15 price objective for the company. Finally, Mizuho dropped their price objective on Adaptimmune Therapeutics from $9.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, May 17th.

Adaptimmune Therapeutics Stock Down 1.7 %

The company’s fifty day moving average price is $1.06 and its two-hundred day moving average price is $1.09. The company has a market cap of $213.73 million, a price-to-earnings ratio of -1.17 and a beta of 2.34.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Adaptimmune Therapeutics had a negative return on equity of 259.68% and a negative net margin of 890.13%. The firm had revenue of $5.68 million for the quarter, compared to the consensus estimate of $4.40 million. On average, equities research analysts predict that Adaptimmune Therapeutics plc will post -0.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Boulder Hill Capital Management LP acquired a new position in Adaptimmune Therapeutics during the 1st quarter worth approximately $143,000. Twin Focus Capital Partners LLC acquired a new position in Adaptimmune Therapeutics during the fourth quarter worth $44,000. JTC Employer Solutions Trustee Ltd acquired a new position in Adaptimmune Therapeutics during the first quarter worth $41,000. Key Client Fiduciary Advisors LLC increased its stake in Adaptimmune Therapeutics by 6.4% in the 4th quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock valued at $267,000 after buying an additional 20,295 shares during the last quarter. Finally, Columbia Advisory Partners LLC bought a new stake in Adaptimmune Therapeutics during the 1st quarter worth about $25,000. Institutional investors and hedge funds own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.